Search the Newsreel

QUEST DIAGNOSTICS ($DGX) Releases Q2 2026 Earnings

Quest Diagnostics Earnings: Strong Quarterly Results Spur Optimistic Outlook for Second Half

What's Going On With Questerre Energy Corporation Stock Thursday?

Quest’s (NYSE:DGX) Q2 CY2026: Beats On Revenue, Stock Soars

Quest's (NYSE:DGX) Q2 CY2026: Beats On Revenue, Stock Soars Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $3.04 billion. Its non-GAAP profit of $3.12 per share was 10.5% above analysts' …

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aquestive Therapeutics, Inc. (NASDAQ:AQST) regarding potential corporate wrongdoing by its officers and/or directors. The firm is encouraging shareholders who purchased Aquestive securities prior to June 16, 2025, and continue to hold them, to contact …

Quest Diagnostics earnings on deck as testing growth accelerates

Quest Diagnostics is set to report second-quarter earnings, with analysts expecting continued revenue and EPS growth. Investors will focus on the company's advanced diagnostics investments, routine testing demand, and use of AI to improve margins, as well as management's full-year outlook. The diagnostic testing …

Quest Diagnostics stock trades steadily as recent earnings and data volumes shape outlook

Quest Diagnostics (DGX) stock performance remains steady, supported by stable revenue growth and modest EPS expansion. The company reported $2.37 billion in revenue and $2.05 diluted EPS in a recent quarter, reflecting operational efficiency despite modest 1.7% revenue growth. With a market capitalization around …

Quest Diagnostics Rallies Ahead of Earnings as Investors Weigh Growth Initiatives | DGX Stock News

Quest Diagnostics Rallies Ahead of Earnings as Investors Weigh Growth Initiatives

Quest Diagnostics stock trades steadily as investors weigh recent revenue growth and dividend income

Quest Diagnostics stock reflects steady fundamentals, with investors focusing on recent revenue trends, earnings resilience, and cash returns via dividends alongside the broader US healthcare diagnostics sector. The company's financials show moderate revenue growth, stable earnings, and a consistent dividend payout, making it a …

DGX4807226 Bond Coupon Profile — Rate & Payments

This article provides the coupon profile for the DGX4807226 bond issued by Quest Diagnostics Incorporated. It details that the current coupon rate is 4.20% and the next payment is scheduled for December 31, 2026. The article highlights the bond's interest payment overview and offers …

Aquestive Therapeutics president and CEO Daniel Barber sells $100,191 in stock

Aquestive Therapeutics President and CEO Daniel Barber sold a total of $100,191 worth of company stock through two transactions on July 15 and July 16, 2026. These sales reduced his direct ownership to 610,574 shares. The sales occurred while the stock was trading at …

Enterprise value to EBITDA forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST

This page provides information on the enterprise value to EBITDA forward for Aquestive Therapeutics, Inc. (NASDAQ:AQST). It is part of a larger financial data and market analysis platform, offering various tools and community features for investors. The content specifically highlights the financial metric for …

Quest Diagnostics Inc. stock underperforms Monday when compared to competitors

Shares of Quest Diagnostics Inc. (DGX) fell 1.43% on Monday, closing at $207.66. This underperformance occurred on a generally negative trading day, with both the S&P 500 Index and Dow Jones Industrial Average also declining. The stock's drop ended a two-day winning streak.

Quest Diagnostics Q2 2026 Earnings Preview — July 23, Street Expects $2.82 EPS

Quest Diagnostics is set to announce its second-quarter earnings on July 23, with analysts expecting $2.82 EPS on revenue of $2.97 billion, representing significant year-over-year growth. Despite a 100% beat rate in its last quarter, analyst EPS estimates have seen a modest downward revision …

Quest Diagnostics stock trades steady as investors weigh recent earnings and volume trends

Quest Diagnostics stock is trading steadily as investors assess its recent earnings and volume trends, driven by diagnostic testing demand and margin performance. The company's financial health is supported by resilient testing volumes, cost-management initiatives, strong cash flow, and strategic investments in technology and …

Quest Diagnostics (DGX) Expands Oncology Test Access, Is The Stock Fully Valued?

Quest Diagnostics (DGX) has expanded access to its oncology tests by integrating them into Flatiron Health’s OncoEMR platform, a move boosting investor interest. Despite recent strong stock performance, Simply Wall St assesses DGX as 5.7% undervalued with a fair value of $223.44, driven by …

Quest Diagnostics | SCHEDULE 13G/A: Others

This article is a financial filing document, specifically a SCHEDULE 13G/A, related to Quest Diagnostics. The "Others" designation suggests a filing by a category of investor other than an institutional manager, perhaps an individual or a passive investor group revealing beneficial ownership.

Behavioral Patterns of HQI and Institutional Flows

This article analyzes behavioral patterns for Hirequest, Inc. (NYSE: HQI), identifying strong near-term sentiment that could shift to neutral mid-term and positive long-term biases. It details specific AI-generated trading strategies with entry/target/stop-loss points for position, momentum, and risk-hedging, alongside multi-timeframe signal analysis for support …

DGX4986719 Bond Risk Profile

This article provides a risk profile for the Quest Diagnostics Incorporated 2.8% bond, identified as DGX4986719. It highlights key metrics for assessing credit risk, such as security level, inflation protection, and issuer rating. The profile aims to help investors evaluate the bond's reliability and …

Aquestive Therapeutics (AQST) CEO Barber sells 25,000 shares between $4.00 and $4.04

Aquestive Therapeutics (AQST) CEO Daniel Barber sold a total of 25,000 common shares on July 15-16, 2026, at prices ranging from $4.00 to $4.04 per share. These transactions were executed under a Rule 10b5-1 trading plan. Following the sales, Barber directly holds 610,574 shares …

Quest Diagnostics stock holds near results driven levels

Quest Diagnostics stock performance is being evaluated based on its recent earnings metrics, including quarterly revenue of $2.62 billion, adjusted diluted EPS of $2.64, and an adjusted operating margin of 15.0%. The company's core diagnostic testing franchise is its primary earnings driver, with testing …

Insider Sell: Aquestive Therapeutics Inc (AQST) President and CE

Aquestive Therapeutics Inc (AQST) President and CEO Daniel Barber sold 25,000 shares of the company on July 16, 2026, reducing his total holdings to 610,574 shares. This transaction follows a pattern of 19 insider sells and no buys over the past year. With the …

Digi Power X (DGX) Registration filing Summary

Digi Power X (DGX) has filed a registration summary outlining its business model, financial performance, and use of proceeds. The company develops and operates advanced data centers for sustainable energy, high-performance computing, Bitcoin mining, and AI/GPU infrastructure. DGX recently closed a $6.6 million private …

Form 4 Aquestive Therapeutics Inc For: 17 July By Investing.com

This article from Investing.com is a regulatory filing update, specifically a Form 4 for Aquestive Therapeutics Inc., dated July 17. It simply announces the availability of this standard insider transaction report for the public record.

Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (NASDAQ:AQST) for alleged corporate wrongdoing. The law firm encourages investors who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist with the investigation. The …

The Bull Case For Quest Diagnostics (DGX) Could Change Following Oncology Test Integration Into OncoEMR - Learn Why

Quest Diagnostics (DGX) has integrated its Haystack MRD ctDNA test and Comprehensive Genomic Profiling services for solid tumors into Flatiron Health’s OncoEMR, making it easier for oncology clinicians to access these advanced diagnostic tests. This move supports Quest's strategy to expand high-value, data-driven testing, …

ETFs Investing in Quest Diagnostics Incorporated Stocks

This article lists various Exchange Traded Funds (ETFs) that hold Quest Diagnostics Incorporated (DGX) stocks. It provides a detailed table including each fund's market value, weight

Quest Diagnostics stock trades steadily as investors weigh steady revenue and margin trends

Quest Diagnostics stock reflects a balance between stable revenue growth and margin pressures. Recent financial results show the company managing the transition from pandemic-related testing to routine services, maintaining mid-single-digit revenue growth and mid-teens operating margins, despite a slight decline in net income. The …

Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Report - Results, Call & Slides

Aquestive Therapeutics, Inc. (AQST) reported its Q3 2025 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -$0.14 against a consensus of -$0.13, and actual revenue of $12.81M compared to an expected $12.97M. The report includes details on past …

DGX.GL Bond Profile — Key Metrics

This article provides key metrics for the DGX.GL bond, issued by Quest Diagnostics, Inc. The bond has a 5.75% coupon rate and matures on January 30, 2040, with an outstanding amount of $249.24 million. Quest Diagnostics, Inc. is a diagnostic testing and information services …

Enterprise value to EBIT forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST

This article provides financial information for Aquestive Therapeutics, Inc. (NASDAQ:AQST), specifically focusing on its enterprise value to EBIT forward. It indicates that the company's financial data and SEC filings are available through TradingView, supported by various financial data providers.

Quest Diagnostics stock holds steady as diagnostics demand underpins long term growth

Quest Diagnostics stock reflects the company's significant position as a major US clinical laboratory operator, benefiting from a steady, long-term demand for diagnostic services. The company's large-scale network, operational efficiency, and role in chronic disease management and public health are key pillars of its …

Form 144 Aquestive Therapeutics For: 15 July By Investing.com

This article from Investing.com announces a Form 144 filing for Aquestive Therapeutics on July 15. Form 144 is a notice of the intent to sell restricted securities, indicating that insiders or affiliates of Aquestive Therapeutics plan to sell shares. The brief piece provides limited …

Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors

Shares of Quest Diagnostics Inc. (DGX) fell 2.05% on Wednesday, closing at $201.77. This underperformance occurred despite a favorable trading session for the broader market, with both the S&P 500 Index and the Dow Jones Industrial Average posting gains. This marked the ninth consecutive …

EnQuest Moves Closer to Completing Major Malaysian Acquisition (ENQ)